Steven Valiquette
Stock Analyst at Mizuho
(3.23)
# 986
Out of 5,182 analysts
128
Total ratings
49.25%
Success rate
2.04%
Average return
Main Sectors:
Stocks Rated by Steven Valiquette
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PHR Phreesia | Maintains: Outperform | $22 → $19 | $8.60 | +120.93% | 3 | Mar 24, 2026 | |
| LFMD LifeMD | Upgrades: Outperform | $6 → $8 | $3.77 | +112.20% | 3 | Mar 16, 2026 | |
| XRAY DENTSPLY SIRONA | Maintains: Neutral | $14 → $16 | $12.22 | +30.93% | 9 | Mar 2, 2026 | |
| GDRX GoodRx Holdings | Maintains: Neutral | $4 → $3 | $2.23 | +34.53% | 2 | Feb 27, 2026 | |
| HSIC Henry Schein | Maintains: Neutral | $81 → $88 | $77.20 | +13.99% | 7 | Feb 25, 2026 | |
| DOCS Doximity | Maintains: Neutral | $45 → $34 | $22.25 | +52.81% | 4 | Feb 10, 2026 | |
| NVST Envista Holdings | Maintains: Neutral | $24 → $27 | $27.38 | -1.39% | 4 | Feb 10, 2026 | |
| CAH Cardinal Health | Maintains: Outperform | $222 → $235 | $214.95 | +9.33% | 8 | Feb 6, 2026 | |
| MCK McKesson | Maintains: Neutral | $880 → $885 | $862.79 | +2.57% | 5 | Feb 5, 2026 | |
| ALGN Align Technology | Maintains: Outperform | $170 → $200 | $184.69 | +8.29% | 13 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $85 → $100 | $69.02 | +44.89% | 3 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $48 | $47.67 | +0.69% | 1 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $340 → $380 | $319.90 | +18.79% | 3 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $50 | $22.43 | +122.92% | 2 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $295 → $325 | $159.09 | +104.29% | 4 | Aug 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $10 | $5.24 | +90.84% | 1 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $126 | $81.36 | +54.87% | 1 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $5.17 | -3.29% | 1 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $142 | $181.95 | -21.96% | 10 | Sep 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 | $85.34 | -35.55% | 6 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $82 → $92 | $210.99 | -56.40% | 10 | Aug 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $565 | $314.19 | +79.83% | 5 | Apr 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $100 | $77.62 | +28.83% | 1 | Mar 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $380 → $400 | $147.51 | +171.17% | 4 | Oct 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Overweight | $107 | $37.26 | +187.17% | 1 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $22 → $17 | $39.35 | -56.80% | 3 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $5 → $12 | $13.92 | -13.79% | 1 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $96 | $106.70 | -10.03% | 3 | Nov 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $105 → $120 | $194.16 | -38.20% | 6 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $117 → $127 | $498.66 | -74.53% | 1 | Apr 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $327 → $358 | $196.21 | +82.46% | 3 | Dec 6, 2019 |
Phreesia
Mar 24, 2026
Maintains: Outperform
Price Target: $22 → $19
Current: $8.60
Upside: +120.93%
LifeMD
Mar 16, 2026
Upgrades: Outperform
Price Target: $6 → $8
Current: $3.77
Upside: +112.20%
DENTSPLY SIRONA
Mar 2, 2026
Maintains: Neutral
Price Target: $14 → $16
Current: $12.22
Upside: +30.93%
GoodRx Holdings
Feb 27, 2026
Maintains: Neutral
Price Target: $4 → $3
Current: $2.23
Upside: +34.53%
Henry Schein
Feb 25, 2026
Maintains: Neutral
Price Target: $81 → $88
Current: $77.20
Upside: +13.99%
Doximity
Feb 10, 2026
Maintains: Neutral
Price Target: $45 → $34
Current: $22.25
Upside: +52.81%
Envista Holdings
Feb 10, 2026
Maintains: Neutral
Price Target: $24 → $27
Current: $27.38
Upside: -1.39%
Cardinal Health
Feb 6, 2026
Maintains: Outperform
Price Target: $222 → $235
Current: $214.95
Upside: +9.33%
McKesson
Feb 5, 2026
Maintains: Neutral
Price Target: $880 → $885
Current: $862.79
Upside: +2.57%
Align Technology
Jan 20, 2026
Maintains: Outperform
Price Target: $170 → $200
Current: $184.69
Upside: +8.29%
Jan 20, 2026
Upgrades: Outperform
Price Target: $85 → $100
Current: $69.02
Upside: +44.89%
Jan 12, 2026
Initiates: Outperform
Price Target: $48
Current: $47.67
Upside: +0.69%
Nov 6, 2025
Maintains: Outperform
Price Target: $340 → $380
Current: $319.90
Upside: +18.79%
Oct 30, 2025
Maintains: Outperform
Price Target: $48 → $50
Current: $22.43
Upside: +122.92%
Aug 29, 2025
Maintains: Outperform
Price Target: $295 → $325
Current: $159.09
Upside: +104.29%
Jul 25, 2025
Initiates: Neutral
Price Target: $10
Current: $5.24
Upside: +90.84%
Dec 4, 2024
Initiates: Outperform
Price Target: $126
Current: $81.36
Upside: +54.87%
Dec 4, 2024
Initiates: Outperform
Price Target: $5
Current: $5.17
Upside: -3.29%
Sep 21, 2023
Maintains: Equal-Weight
Price Target: $142
Current: $181.95
Upside: -21.96%
Aug 4, 2023
Maintains: Overweight
Price Target: $55
Current: $85.34
Upside: -35.55%
Aug 2, 2023
Maintains: Overweight
Price Target: $82 → $92
Current: $210.99
Upside: -56.40%
Apr 14, 2023
Maintains: Overweight
Price Target: $565
Current: $314.19
Upside: +79.83%
Mar 30, 2023
Maintains: Overweight
Price Target: $110 → $100
Current: $77.62
Upside: +28.83%
Oct 28, 2022
Maintains: Overweight
Price Target: $380 → $400
Current: $147.51
Upside: +171.17%
Jul 28, 2022
Reinstates: Overweight
Price Target: $107
Current: $37.26
Upside: +187.17%
Apr 18, 2022
Downgrades: Equal-Weight
Price Target: $22 → $17
Current: $39.35
Upside: -56.80%
Jun 11, 2021
Upgrades: Overweight
Price Target: $5 → $12
Current: $13.92
Upside: -13.79%
Nov 23, 2020
Upgrades: Overweight
Price Target: $96
Current: $106.70
Upside: -10.03%
Apr 30, 2020
Reiterates: Neutral
Price Target: $105 → $120
Current: $194.16
Upside: -38.20%
Apr 22, 2020
Maintains: Overweight
Price Target: $117 → $127
Current: $498.66
Upside: -74.53%
Dec 6, 2019
Maintains: Overweight
Price Target: $327 → $358
Current: $196.21
Upside: +82.46%